Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models

Urology

Volumn 82, Issue 2, 2013, Pages 387-393

  Xu, Tianyuan ^a   Zhu, Zhaowei ^a   Zhang, Xiaohua ^a   Wang, Xianjin ^a   Zhong, Shan ^a   Zhang, Minguang ^a   Shen, Zhoujun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; CALCULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHINESE; CONTROLLED STUDY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER SCORING SYSTEM; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPANISH UROLOGICAL CLUB FOR ONCOLOGICAL TREATMENT SCORING SYSTEM; TRANSURETHRAL RESECTION; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84880924402     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.04.007     Document Type: Article

References (30)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. B.W. van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in nonmuscle invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430 442
3. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 475
4. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
5. B.W. van Rhijn, T.C. Zuiverloon, and A.N. Vis Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer Eur Urol 58 2010 433 441
6. S. Sakano, H. Matsuyama, and K. Takai Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines BJU Int 107 2011 1598 1604
7. V. Hernandez, E. De La Pena, and M.D. Martin External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer World J Urol 29 2011 409 444
8. J. Fernandez-Gomez, R. Madero, and E. Solsona The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
9. R. Pillai, D. Wang, and E.K. Mayer Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort Sci World J 11 2011 751 759
10. J. Fernandez-Gomez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model J Urol 182 2009 2195 2203
11. H.M. Rosevear, A.J. Lightfoot, and K.G. Nepple Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-alpha J Urol 185 2011 67 71
12. T. Matsuda, and K. Katanoda Comparison of time trends in bladder cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents vol. IV-VIII Jpn J Clin Oncol 38 2008 85 86
13. B. Shi, K. Zhang, and J. Zhang Relationship between patient age and superficial transitional cell carcinoma characteristics Urology 71 2008 1186 1190
14. J.X. Chen, N. Deng, and L.W. Chen Multivariate analysis of recurrence factors for non muscle-invasive bladder urothelial carcinomas Zhonghua Yi Xue Za Zhi 90 2010 1992 1994
15. L.R. Koskela, M. Poljakovic, and I. Ehrén Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer Nitric Oxide 27 2012 185 191
16. M.R. Saban, M.A. O'Donnell, and R.E. Hurst Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guérin (BCG), LPS, and TNF-alpha BMC Immunol 9 2008 4
17. H.W. Herr Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy Urology 70 2007 65 68
18. F. Saint, J.J. Patard, and P. Maille Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer J Urol 167 2002 364 367
19. F.N. Joudi, B.J. Smith, and M.A. O'Donnell The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634 1639
20. J. Palou, R.J. Sylvester, and O.R. Faba Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118 125
21. D.L. Lamm, D.R. Riggs, and C.L. Traynelis Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder J Urol 153 1995 1444 1450
22. A. Pawinski, R. Sylvester, and K.H. Kurth A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer J Urol 156 1996 1934 1940
23. J.A. Witjes, and K. Hendricksen Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results Eur Urol 53 2008 45 52
24. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190
25. A. Tsallas, J. Jackson, and H. Burt The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations Cancer Chemother Pharm 68 2011 431 444
26. N. Birare, B.A. Lwaleed, and A.J. Cooper Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure J Urol 182 2009 2472 2476
27. R.F. Han, and J.G. Pan Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials Urology 67 2006 1216 1223
28. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
29. R.J. Sylvester, M.A. van der, and D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
30. A. Bohle, and P.R. Bock Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682 686